PRNewsWire
24 Sept 2026, 23:17 UTC · 1h ago
Verdict
Headline takes no side. We score RGNX +0.90 across two claims — strongly bullish.
+0.90strongly bullish
More positive than 95% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish · 2 new · 0 priced in
Three-year data for surabgene lomparvovec (Dose Level 3) showed 60% of participants (6/10) achieved a > 2-step improvement on the Diabetic Retinopathy Severity Scale (DRSS) without additional treatment.
Newannounced today, Sept 24, 2026
More positive than 93% of claims this week
No new sura-vec-related safety signals or intraocular inflammation were observed through three years in 17 participants using short-course prophylactic topical steroids.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
Newannounced today, Sept 24, 2026
So whatConfirming long-term safety of the AAV 8 vector minimizes the risk of a sudden FDA clinical hold during later stage trials.
More positive than 78% of claims this week
Which stocks this story touches
More positive than 95% of ticker scores this week
The company announced positive three-year durability data for its gene therapy surabgene lomparvovec in treating diabetic retinopathy.
More positive than 65% of ticker scores this week
The company is a partner in the development of sura-vec, which showed encouraging long-term efficacy data.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
2h ago
—
RGNX hasn't traded since this ran. Last close $7.24 (Sep 24); the reaction starts at the next open.
RGNX chart →
